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Information-adaptive clinical trials: a selective recruitment
design
James E. Barrett
University College London, London, U.K.
Summary. We propose a novel adaptive design for clinical trials with time-to-event outcomes
and covariates (which may consist of or include biomarkers). Our method is based on the
expected entropy of the posterior distribution of a proportional hazards model. The expected
entropy is evaluated as a function of a patient’s covariates, and the information gained due
to a patient is defined as the decrease in the corresponding entropy. Candidate patients
are only recruited onto the trial if they are likely to provide sufficient information. Patients
with covariates that are deemed uninformative are filtered out. A special case is where all
patients are recruited, and we determine the optimal treatment arm allocation. This adap-
tive design has the advantage of potentially elucidating the relationship between covariates,
treatments, and survival probabilities using fewer patients, albeit at the cost of rejecting some
candidates. We assess the performance of our adaptive design using data from the German
Breast Cancer Study group and numerical simulations of a biomarker validation trial.
Keywords: Adaptive trial design; Optimal allocation; Proportional hazards model
1. Introduction
Adaptive clinical trials offer a potentially more efficient and ethical way to conduct clin-
ical trials. Covariate-adaptive designs try to ensure that the distributions of covariates
across different arms are balanced, thus resulting in more comparable cohorts on each arm
(Pocock and Simon, 1975; Taves, 1974). Response-adaptive randomisation attempts to
allocate more patients to the effective treatment arms. As the trial progresses and more
information is acquired on the efficacies of each treatment arm the allocation probabilities
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shift towards the more effective treatments. Zhang and Rosenberger (2007) develop an
optimal response-adaptive design under exponential and Weibull parametric models for
time-to-event outcomes. See Yin (2012) for a good overview of adaptive designs.
We regard the primary goal of a clinical trial as establishing a statistical relationship
between covariates, treatments, and survival outcomes. As we will show, not all patients on
a trial provide the same amount of statistical information. Some covariate values are more
informative than others. In addition, the informativeness of a covariate value will depend
on what has been observed so far in the trial. As an example, consider two scenarios where
a patient with particular covariate values is available for recruitment. In the first scenario
another patient with precisely the same covariate values has already been recruited. In
the second scenario suppose the candidate’s covariates come from a region of covariate
space that has not previously been sampled. Intuitively we expect the candidate to be
more informative in the second scenario since they provide access to previously unobserved
covariates values and outcomes.
Our aim in this paper is to address a practical question: given limited resources and
the observation that not all patients are equally informative, what is the optimal way to
conduct a clinical trial? We propose that it may be advantageous to selectively recruit
and allocate patients on the basis of how much information they are likely to provide.
Covariates are measured for candidate patients, and based on those values and what has
been inferred from the trial up to that point a recruitment probability is computed. In
other words, we filter out patients that are unlikely to significantly reduce the uncertainty
surrounding model parameters.
Predictive biomarkers, which indicate whether a patient is likely to respond well to
a particular treatment or not, are increasingly useful in the drive towards personalised
medicine and targeted therapy. A potential application of our selective-recruitment design
would be to validate a biomarker by looking at treatment-biomarker interaction terms in
a proportional hazards model. We test this using numerical simulations. Sargent et al.
(2005) discuss alternative adaptive designs for validating predictive biomarkers.
Our filtering approach is similar in spirit to some existing designs. Freidlin and Simon
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(2005) propose a trial design which attempts to find a gene signature that will identify
a subset of ‘sensitive’ patients who are more likely to respond to the treatment. In a
randomised discontinuation design (Rosner et al., 2002) patients who fail to respond to a
treatment in the first phase of the trial are dropped from the second part, thereby isolating
a responsive subset of patients with a stronger statistical signal. Another type of trial
known as ‘enrichment designs’ (Temple, 2010) enrich the recruited cohort with patients
who are more likely to have the event of interest. For example, patients with a particular
biomarker. Given that more events of interest are observed greater statistical power can
be achieved within the enriched cohort.
We assume a proportional hazards model with a constant baseline hazard rate. The
entropy of the posterior distribution is a useful way to quantify our uncertainty regarding
the model parameters. As the trial progresses, and the space of plausible parameter values
shrinks, the entropy decreases. The informativeness of a candidate is defined as the reduc-
tion in expected entropy in the hypothetical scenario where they are added to the cohort
of existing recruits. The ideal candidate at time t is defined as the patient that would
achieve the greatest possible reduction in expected entropy. By comparing the current
candidate to the ideal candidate we can obtain a recruitment probability. The posterior is
constructed using outcomes from all patients accrued up until time t. Patients who have
not experienced any events are considered to be right-censored. Therefore, the recruitment
probability changes dynamically as more events and patients are observed. An arm alloca-
tion probability can also be computed based on which arm has the lowest expected entropy.
We also implement this in a more traditional setting where all candidates are recruited.
In Section 2 we provide the mathematical details and describe some approximations
which are required. Results from experimental data generated by the German Breast Can-
cer Study group and numerical simulations are presented in Sections 3 and 4 respectively.
Discussion on the practical applicability of our approach and concluding remarks are given
in Section 5.
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2. An information based adaptive protocol
2.1. Proportional hazards model
Suppose that Nt patients have been recruited onto the trial at time t. Observed data are
denoted by Dt = {(x1, t1,∆1), . . . , (xNt , tNt ,∆Nt)} where xi ∈ Rd is a vector of covariates
for patient i (this vector may include biomarker values or treatment indicator variables).
If patient i is censored then ∆i = 0 and ti is the time of censoring, otherwise the primary
event occurred at time ti and ∆i = 1. Patients who have not experienced any event by t
are considered right censored. We assume a proportional hazards model with a constant
baseline hazard rate λ ∈ (0,∞):
h(ti|xi, λ,β) = λeβ·xi for i = 1, . . . , Nt (1)
where β ∈ Rd is a vector of regression coefficients. The covariates are assumed to be drawn
from a known population distribution p(x). The data likelihood is
p(Dt|λ,β) =
Nt∏
i=1
(
λeβ·xi
)∆i
exp(−λtieβ·xi)p(xi). (2)
Using Bayes’ rule we can write the posterior as
p(λ,β|Dt,θ) = p(Dt|λ,β)p(λ|θ)p(β|θ)
p(Dt|θ) (3)
where p(Dt|θ) is the marginal likelihood. The vector θ contains hyperparameters that are
required for the prior distributions. For the prior over λ we choose λ ∼ Gamma(κ0, χ0),
with shape and scale hyperparameters κ0 and χ0 respectively, and β ∼ N (0, α20I). The
value of θ = (κ0, χ0, α
2
0) is fixed and we will henceforth drop the dependence on θ for the
sake of notational compactness.
2.2. Entropy as a measure of patient informativeness
At time t we have recruited Nt patients onto the trial. Suppose that a candidate patient
with covariates x∗ has presented and we wish to estimate how much information we expect
the candidate to provide if they are to be recruited. The information gain is defined as the
Information-adaptive clinical trials 5
reduction in the expected entropy of the posterior (3). The entropy is defined as
h(Dt) = −〈log p(λ,β|Dt)〉p(λ,β|Dt) . (4)
The notation 〈· · · 〉p denotes the expectation with respect to the density p. We then add
the candidate to the existing cohort and take the expectation with respect to the unknown
t∗:
H(x∗|Dt) = 〈h(Dt ∪ {x∗, t∗})〉p(t∗|x∗,Dt) (5)
where the argument of h is the union of Dt and the additional uncensored observation
{x∗, t∗} and where
p(t∗|x∗, Dt) = 〈p(t∗|x∗, λ,β)〉p(λ,β|Dt) . (6)
The time-to-event density is p(t∗|x∗, λ,β) = λeβ·x∗exp(−λt∗eβ·x∗). This can be used to
define an objective function E that will be used to determine the recruitment probability
for the candidate
E(x∗|Dt) = h(Dt)−H(x∗|Dt). (7)
2.3. Mathematical approximations
The expectation (4) is analytically intractable. Consequently, we develop a variational ap-
proximation of the the posterior q(λ,β) ≈ p(λ,β|Dt) with q(λ,β) = q(λ)q(β). The purpose
of a variational approximation is to approximate the posterior with a form that is more
amenable to analytical integration (Bishop, 2006, Chapter 10). For the variational distribu-
tions q we choose a log-Normal distribution, log λ ∼ N (µ1, σ21), and a multivariate Normal
distribution for the regression coefficients, β ∼ N (µ0,Σ0) with Σ0 = diag(σ201, . . . , σ20d). To
achieve a ‘good’ approximation we minimise the Kullback-Leibler divergence between the
distributions q and p with respect to the variational parameters (µ1, σ
2
1,µ0, σ
2
01, . . . , σ
2
0d):
KL(q||p) =
〈
log
[
q(λ)q(β)
p(λ,β|Dt)
]〉
q(λ)q(β)
= 〈log q(λ)〉q(λ) + 〈log q(β)〉q(β) − 〈log p(λ,β|Dt)〉q(λ)q(β) . (8)
6 James E. Barrett
This is convenient since the first two terms give the entropy of the variational distribution
which is required in (5). Equation (8) is explicitly calculated in Appendix A.
In addition, the expectations (5, 6) are analytically intractable. We make two further
approximations:
(a) p(t∗|x∗, λ,β) = δ(t∗ − tˆ) where tˆ = 〈t∗〉p(t∗|x∗,λ,β) = (λeβ·x
∗
)−1.
(b) p(λ,β|Dt) = δ(λˆ− λ)δ(βˆ − β) where (λˆ, βˆ) = argmax(λ,β)p(λ,β|Dt).
The Dirac delta function δ(x) is loosely defined by δ(0) =∞ and is zero elsewhere. These
approximations allow evaluation of the integrals (5, 6) and, additionally, it is computa-
tionally faster to obtain (λˆ, βˆ) rather than numerically integrating (5, 6). Combining the
above approximations we can write tˆ = (λˆeβˆ·x∗)−1 and obtain
Hˆ(x∗|Dt) = hˆ(Dt ∪ {x∗, tˆ}) (9)
hˆ(Dt) = −〈log q(λ)〉q(λ) − 〈log q(β)〉q(β) . (10)
These can be substituted into (7) to obtain an approximated objective function Eˆ(x∗|Dt).
Evaluation of these expressions require numerical optimisation of (3) and (8) in order to
evaluate, but this is computationally feasible. Note that estimates of λ and β could be
unstable at the early stages of the trial when few patients have been recruited. In this
case, one could implement a ‘burn in’ phase where selective recruitment only begins after
a certain number of patients have been recruited.
2.4. Obtaining a recruitment and allocation probability
Once a candidate patient presents with covariates x∗ we would like to define a recruitment
probability ρ(x∗|Dt). In general, we can write x∗ = [y∗, z] where y∗ are clinical covariates
or biomarkers and z indicates the allocated treatment arm. Suppose there are K arms in
total and z ∈ {z1, . . . , zK} where zk indicates allocation to arm k. The first step is to
define the allocation probability to treatment arm k as
p(k|x∗, Dt) = Eˆ(y
∗, zk|Dt)∑K
j=1 Eˆ(y
∗, zj |Dt)
for k = 1, . . . ,K. (11)
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A treatment arm is chosen at random according to this distribution and is denoted by z∗.
Secondly, we define the ideal candidate as yI = argminyEˆ(y, z
∗|Dt). The ideal candidate
would give us the greatest reduction in expected entropy. A recruitment probability is
given by
ρ(x∗|Dt) = f0
(
Eˆ(y∗, z∗|Dt)
Eˆ(yI , z
∗|Dt)
)
(12)
where f0 is some function that remains to be specified. Since the argument of f0 must lie in
the interval [0, 1] we can choose f0 to be the identity function in which case the closer the
candidate is to the ideal patient the higher the probability of recruitment. Alternatively,
we can choose f0(s) = θ(s− p0) for a specified threshold p0. The step function θ(s) = 0 if
s ≤ 0 and θ(s) = 1 otherwise. This results in deterministic recruitment. A more general
option is f0(s) = (1 + tanh(s/β0 − p0))/2 which is equivalent to deterministic recruitment
when β0 → 0. This allows the practitioner to implement a desired level of stringency in
the recruitment process.
3. The German Breast Cancer Dataset
We applied our method to data obtained from the German Breast Cancer Study (GBCS)
described in Hosmer et al. (2008, Section 1.3). Our goal is to infer the parameters for a
single covariate in order to assess how our adaptive protocol performs. The data consist of
time-to-event outcomes for 686 patients recruited between July 1984 and December 1989.
There are eight covariates in total. We decided to use tumour size (mm) for a univariate
analysis because a good spread (1st quartile = 20 mm, median = 25 mm, 3rd quartile = 35
mm) would make it suitable for filtering patients according to the covariate. Importantly,
the dataset also contains the date at which each patient is diagnosed with primary node
positive breast cancer so we can easily calculate the waiting-time between patients. This
allows us to effectively ‘re-run’ the trial. The primary event was recurrence.
To assess the information-adaptive design we decided to recruit a total of NT = 100
patients. We used deterministic recruitment with a cutoff of p0 = 0.5. The trial was
terminated after 10 years. We compared this to a randomised clinical trial (RCT) in which
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Fig. 1. Plot of the posterior entropy (10) for the RCT and ACT as a function of time. The vertical
ticks indicate times at which a patient was recruited. The sharp drop at ≈ 0.75 years corresponds
to the first primary event occurring.
Table 1. Inferred parameters and entropies of the full GBCS dataset (Full), the adaptive clinical trial
(ACT), and the randomised clinical trial (RCT). In brackets are 95 percent confidence intervals and p
is corresponding the p-value. Ntotal is the total number of recruits, Nreject is the number of rejected
candidates, and tR is the recruitment time in months.
Ntotal Nreject tR λ β entropy
Full 686 0 67 0.13 0.36 (0.19,0.52), p = 6.1× 10−6 -4.54
ACT 100 278 31 0.11 0.44 (0.21,0.66), p = 4.2× 10−5 -3.49
RCT 100 0 11 0.14 0.11 (-0.27,0.48), p = 0.29 -2.83
the first 100 patients are recruited. The same proportional hazards model as Section 2.1
was used to analyse the RCT. The covariate values were median-centred and rescaled by 25
mm. The population density was assumed constant. We impose a uniform prior between
±1 for the ideal covariate xI . Hyperparameters were set to (κ0, χ0, α20) = (3, 1, 4).
It took approximately 1 year to recruit 100 patients onto the RCT. The adaptive clin-
ical trial (ACT) took approximately 2.5 years, during which a total of 278 patients were
rejected. In Figure 1 the posterior entropies for both the ACT and RCT are plotted. Ini-
tially the entropies are largely determined by the priors over λ and β but quickly drop as
patients are recruited, although not monotonically. In the first 2.5 years of the trial the
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RCT has a lower entropy which is presumably due to the fact that more patients have been
recruited compared to the ACT. Towards the end of the trial the ACT has a lower entropy
due to a more informative cohort. Both entropies continue to decrease after recruitment
has finished as more events are observed.
Table 1 shows the inferred model parameters (evaluated after 10 years) from the original
dataset, the ACT, and the RCT. The ACT results in a significant non-zero value for β
that is close to the value obtained using the full dataset (with N = 686). The RCT fails
to infer any significant value.
In order to gain some intuition for how the recruitment probabilities are determined we
have plotted the expected entropy as a function of the covariate x at various time points in
Figure 2. We note that the function tends to have one maximum and two minima at x = ±1.
This general shape is due to the nature of the proportional hazards model since extreme
values of x will diminish the space of plausible parameter values more so than values close
to zero, and consequently are more informative. The dashed line is the entropy below which
a candidate will be recruited. In (a) the trial has started at t = 0 with two patients. There
is a strong preference for individuals towards ±1. The next candidate (at t = 34 days) had
x∗ = −0.52 and so was recruited. In (b), some patients with covariate values > 1 have
been recruited and this encourages recruitment of negative covariate values. At t = 267
days no primary events have occurred. In (c), after t = 268 days the first primary event
occurs for a patient with a positive covariate value. This additional piece of information
further increases the benefit of recruiting negative covariate values over positive ones. Note
that the vertical scale changes. This illustrates that the recruitment probability changes
dynamically, and depends on the observed events and covariate values of the existing cohort.
We conclude that in general we gain more information from covariate values that have been
under-sampled or values where few primary events have occurred.
Individuals with covariates values far from zero will have the greatest reduction in
expected entropy. This is because these terms will dominate the data likelihood in a
proportional hazards model. Consequently, the covariate distribution in the ACT can
differ considerably from the population distribution. Figure 3 shows the empirical covariate
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Fig. 2. The expected entropy (9) as a function of x at various times during the ACT.
distributions for the original dataset and both trials. Due to the shape of the expected
entropy function (see Figure 2) patients towards ±1 were more likely to be recruited in
the ACT. Consequently, almost no patients with x ≈ 0 were recruited. The RCT density
resembles the density of the full dataset.
4. Numerical simulation studies
Here we consider a scenario where the covariates consist of a two-dimensional biomarker
yi = (yi1, yi2) and patients are given one of three treatments denoted by zi = (zi1, zi2, zi3).
A patient given treatment one would have zi = (1, 0, 0), treatment two would have zi =
(0, 1, 0), and so forth. We are interested in whether there is any interaction between the
biomarker and treatments, i.e. is the biomarker predictive. A proportional hazards model
with interaction terms is assumed:
h(t|yi, zi, λ,β) = λeβ1yi1zi1+β2yi1zi2+β3yi1zi3+β4yi2zi1+β5yi2zi2+β6yi2zi3 . (13)
This gives a total of six regression coefficients and the baseline hazard λ to be inferred. In
all simulations we compared an adaptive trial to a randomised one.
To simulate survival data we generate a random vector y = (y1, y2) where yi ∼
uniform(−1,+1) or yi ∼ N (0, 0.5) for i = 1, 2. A treatment arm z is chosen (either
randomly or according to (11)). A random number w ∼ uniform(0, 1) is generated, and an
event time is given by the inverse of the cumulative distribution t = −e−β·x log(1 − w)/λ
where x ∈ R6 contains the same product terms between y and z as (13). Patients are
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Figure 3: Kernel smoothed empirical covariate densities (Gaussian kernel, bandwidth = 0.2)
for (a) the full GBCS dataset, (b) the ACT, and (c) the RCT. Due to the shape of the
expected entropy function (see Figure 2) patients towards ±1 were more likely to be recruited
in the ACT. Consequently, almost no patients with x ⇡ 0 were recruited. The RCT density
resembles the density of the full dataset.
3.2 Numerical simulation studies
Here we consider a scenario where the covariates consist of a two-dimensional biomarker yi =
(yi1, yi2) and patients are given one of three treatments denoted by zi = (zi1, zi2, zi3). A patient
given treatment one would have zi = (1, 0, 0), treatment two would have zi = (0, 1, 0), and so forth.
We are interested in whether there is any interaction between the biomarker and treatments, i.e. is
the biomarker predictive. A proportional hazards model with interaction terms is assumed:
h(t|yi, zi, , ) =  e 1yi1zi1+ 2yi1zi2+ 3yi1zi3+ 4yi2zi1+ 5yi2zi2+ 6yi2zi3 . (11)
This gives a total of six regression coe cients and the baseline hazard   to be inferred. In all
simulations we compared an adaptive trial to a randomised one.
To simulate survival data we generate a random vector y = (y1, y2) where yi ⇠ uniform( 1,+1)
for i = 1, 2. A treatment arm z is chosen (either randomly or adaptively). A random number w ⇠
uniform(0, 1) is generated, and an event time is given by the inverse of the cumulative distribution
t =  e  ·x log(1  w)/  where x 2 R6 contains the same product terms between y and z as (11).
Patients are censored at random with probability pcens 2 [0, 1]. If an individual is censored then the
time-to-censoring is drawn from a uniform density between 0 and t. The first patient to be generated
is recruited onto both the ACT and RCT. The waiting time until the next patient is drawn from
an exponential density with rate parameter ⇠. Hyperparameters were set to (0, 0,↵
2
0) = (3, 1, 4).
 1  2  3  4  5  6  
ACT 0.376 0.367 0.360 0.385 0.361 0.385 0.00083
RCT 0.386 0.396 0.373 0.371 0.366 0.399 0.00080
Table 2: Mean square error between inferred and ‘true’ model parameters over 1,000 simu-
lations. Comparison between random and adaptive trials without selective recruitment.
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Fig. 3. Kernel smoothed empirical covariate densities (Gaussian kernel, bandwidth = 0.2) for (a)
the full GBCS dataset, (b) the ACT, and (c) the RCT.
Table 2. Mean square error between inferred and ‘true’ model parameters over 500 simulations.
Comparison between both random and adaptive trials without selective recruitment and uniform
and Gaussian distributed covariates.
β1 β2 β3 β4 β5 β6 λ
ACT (Uniform) 0.348 0.374 0.361 0.384 0.418 0.352 0.00080
RCT (Uniform) 0.364 0.347 0.401 0.389 0.396 0.384 0.00084
ACT (Gaussian) 0.499 0.5120 0.487 0.438 0.445 0.430 0.00085
RCT (Gaussian) 0.470 0.494 0.504 0.471 0.518 0.435 0.00084
cens red at random with probability pc ∈ [0, 1]. If an individual is censored then the
time-to-censoring is drawn from a uniform density between 0 and t. The first patient to
be generated is recruited onto both the ACT and RCT. The waiting time until the next
patient is drawn from an exponential density with rate parameter ξ. Hyperparameters
were set to (κ0, χ0, α
2
0) = (3, 1, 4).
4.1. Adaptive allocation without selective recruitment
In these simulations all patients were recruited. A total of N = 50 patients were recruited
onto both trials. The trial was terminated after t = 100 arbitrary units of time. The
rate parameter for waiting times was ξ = 6, and pc = 0.5. Model parameters were set to
β = (0.8,−0.5, 1.1,−0.7, 0.6, 0.1) and λ = 0.1. In the ACT the expected entropy was used
to determine which treatment arm each individual was allocated to as described in Section
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2.4. In the RCT patients were allocated to one of the three arms at random.
A total of 500 simulations were run. We computed the mean square error between the
inferred model parameters and the ‘true’ values used to generate the data. As shown in
Table 2 we found essentially no difference between the randomised and adaptive trials for
either uniformly or Gaussian distributed covariates. We found that the entropy at the
end of the ACTs with uniform covariates was on average slightly lower than the RCTs
(2.14 and 2.20 respectively), although the difference was statistically significant (p-value
0.017 with a one-sided paired t-test). For Gaussian distributed covariates the difference in
entropies was insignificant. We also performed a chi-squared test to see if the allocation
proportions of patients across arms differed from a uniform distribution. Each simulated
trial was tested and we found no p-values less than 0.05 for either uniform or Gaussian
distributed covariates. Since the chi-squared test was repeated for each trial the p-values
were corrected for multiple hypothesis testing by controlling the false discovery rate (using
the method of Benjamini and Hochberg (1995)) with the ‘p.adjust’ R function.
4.2. Adaptive allocation and recruitment
In these simulations the same parameters as above were used but patients were recruited
onto the ACT selectively with a threshold of p0 = 0.66. Over 500 simulations we found that
the mean square error between the inferred and ‘true’ parameters was considerably lower
in the ACTs than the RCTs as shown in Table 3. For uniformly distributed covariates
48.9% of the inferred parameter values were significant (at 0.05) in the ACT compared to
39.2% in the RCTs. Furthermore, the mean entropy at the end of the ACTs was 0.93,
compared to 2.23 in the RCTs. On average 140.7 (standard deviation 42.9) individuals are
rejected.
In the case of Gaussian distributed covariates the difference is more pronounced. 50.4%
of parameters were significant in the ACT compared to 35.0% in the RCT. An average of
240.0 patients were rejected (standard deviation 61.9). Due to the Gaussian distribution
there are more patients in the less informative region around zero. Therefore the number
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Table 3. Mean square error between inferred and ‘true’ model parameters over 500 simulations.
Comparison between random and adaptive trials with selective recruitment.
β1 β2 β3 β4 β5 β6 λ
ACT (uniform) 0.324 0.279 0.313 0.342 0.279 0.306 0.00079
RCT (uniform) 0.401 0.335 0.408 0.375 0.367 0.361 0.00081
ACT (Gaussian) 0.266 0.289 0.278 0.217 0.253 0.262 0.00085
RCT (Gaussian) 0.444 0.553 0.509 0.521 0.502 0.478 0.00082
of rejections is higher and the benefit more substantial.
We also explored the effect of the threshold p0 on the trial results. When p0 = 0.33 we
found that the MSE (averaged over the six beta values) was 0.287 in the ACT compared to
0.372 in the RCT with 44.0% of inferred parameters reaching statistical significance in the
ACT compared to 39.6% in the RCT. An average of 22.0 patients were rejected (standard
deviation 6.45). When the threshold was increased to p0 = 0.90 the MSE was 0.358 versus
0.363, and the proportion of significant parameters was 41.7% versus 39.3%, in the RCT
and ACT respectively. On average 237.3 (standard deviation 86.5) patients were rejected.
This suggests that setting the threshold too high can be counterproductive.
5. Discussion
The practicality of our proposed design will depend on various economic and ethical con-
siderations as well as the characteristics of each particular trial and the study population.
For instance, if a covariate is relatively inexpensive to measure when compared to the costs
of recruitment (treatment provision, follow-up, administration) then it may be sensible
to selectively recruit informative patients. A large pool of patients can be inexpensively
screened and then resources concentrated on those which are likely to provide the most
information. In this case a selective recruitment design could result in significant cost
reductions since fewer recruits are required overall.
Clinical trials are not primarily intended to be therapeutic, but rather as a means to
generate medical evidence. Recruited patients may be exposed to treatments that are
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ineffective (e.g. a placebo) or that are possibly even harmful. Our proposed design offers
the possibility to conduct a trial using fewer patients than a traditional randomised design.
This may be ethically attractive in some cases since ultimately fewer patients are offered
treatment options with uncertain efficaciousness.
In a selective recruitment design the decision to recruit and allocate a patient can also
take into account the probability of a successful response to treatment (although this was
outside the scope of this paper). Patients can be recruited and allocated in a manner that
balances the statistical informativeness of a decision against the potential benefit or harm
to that individual. The decision making process must balance individual and collective
benefits. Maximising statistical information offers a collective benefit to all patients outside
the trial (both current and future) who could benefit from the trial findings. Naturally this
must be offset by what is best for the trial participants. What our proposed design offers the
practitioner is a framework to balance individual versus collective ethical considerations.
Selective recruitment designs suffer from a number of drawbacks, one of which is longer
recruitment times. If the patient accrual rate is low it may render the overall recruitment
period unfeasible. Selective recruitment designs are therefore only appropriate in situa-
tions where patients accrue relatively quickly or where longer recruitment periods are an
acceptable compromise.
One of the consequences of a proportional hazards model is that the most informative
patients tend to have extreme values of covariates. As a result the distribution of re-
cruited patients may differ from the population distribution which might make it difficult
to generalise results from the trial to the general population. Thus, some generalisability
is sacrificed in return for greater statistical power. If this was deemed undesirable one
could introduce a sufficient level of random sampling in addition to preferential accrual of
informative patients. Each candidate patient has a minimum probability of recruitment
with informative patients having a higher probability. Thus, selective recruitment need not
be an all or nothing process; it can be used to enrich the trial with informative patients to
a desired degree.
Finally, in the case of model misspecification undesirable biases may be introduced into
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the dataset because the model choice influences the covariate distribution considerably. An
additional limitation is that it is not yet clear how to estimate the sample size required
for a certain level of statistical power — a calculation that is typically used when planning
new trials.
In summary, our novel information-adaptive selective recruitment clinical trial design
will reject non-informative patients. Individuals who are more likely to clarify the values
of our model parameters are more likely to be recruited. We have demonstrated with both
experimental and simulated data the feasibility of our approach. Statistically significant
inferences can be achieved using fewer patients with a selective recruitment design than a
randomised trial, although we found that treatment arm allocation using an entropy based
measure (without selective recruitment) did not offer any improvement over a randomised
design. Such a design may offer a more economical or ethically attractive route to discover
the relationship between biomarkers, treatments, and survival outcomes.
It will be interesting to extend this work beyond the proportional hazards assumption to
more complex survival models. Incorporation of response-adaptive protocols offer another
promising extension. Throughout this work we have assumed a uniform population density.
In the case of a non-uniform density it may be desirable to incorporate this into the
definition of an ideal candidate such that an ideal candidate is both informative and likely
to be observed. This will require further investigation. Further extensions of the model
could include alternative outcomes such as binary or continuous measurements.
A. Derivation of the Kullback-Leibler divergence
The first two terms of the Kullback-Leibler divergence (8) in Section 2.3 are simply mi-
nus the entropies of the variational distributions. These are 〈log q(λ)〉q(λ) = −(1/2 +
log(2piσ21)/2 + µ1) and 〈log q(β)〉q(β) = −
∑d
ν=1 log(2pieσ
2
0ν)/2. The third term from (8) is
−N1t 〈log λ〉q(λ) −Φt · 〈β〉q(β) + 〈λ〉q(λ)
Nt∑
i=1
ti
〈
eβ·xi
〉
q(β)
− 〈log p(λ|κ0, χ0)〉q(λ) −
〈
log p(β|α20)
〉
q(β)
(14)
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where N1t is the number of non-censored events up until time t and Φt =
∑
i:∆i=1
xi. It
is straightforward to show 〈log λ〉q(λ) = µ1, 〈λ〉q(λ) = eµ1+σ
2
1/2 and 〈β〉q(β) = µ0. The
following result is needed (Coolen et al., 2005, Appendix D):∫
dz
e−
1
2
(z−µ)·A−1(z−µ)+b·z
(2pi)d/2|A|1/2 = e
µ·b+ 1
2
b·Ab (15)
from which it follows
〈
eβ·xi
〉
q(β)
= eµ0·xi+
1
2
xi·Σ0xi . Note that (15) also defines the moment
generating function for a multivariate normal distribution with mean µ and covariance
matrix A. The terms relating to the priors are
〈
log p(β|α20)
〉
q(β)
= −∑ν(σ20ν + [µ0]2ν)/2α20
and 〈log p(λ|κ0, χ0)〉q(λ) = (κ0 − 1) 〈log λ〉q(λ) − χ−10 〈λ〉q(λ) where [µ0]ν denotes the νth
component of µ0.
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